Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 31;9(4):730.
doi: 10.3390/microorganisms9040730.

Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections

Corneliu Ovidiu Vrancianu  1   2 , Elena Georgiana Dobre  1 , Irina Gheorghe  1   2 , Ilda Barbu  1   2 , Roxana Elena Cristian  3 , Mariana Carmen Chifiriuc  1   2
Affiliations
Review

Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections

Corneliu Ovidiu Vrancianu et al. Microorganisms. .

Abstract

Carbapenem-resistant Enterobacterales (CRE) are included in the list of the most threatening antibiotic resistance microorganisms, being responsible for often insurmountable therapeutic issues, especially in hospitalized patients and immunocompromised individuals and patients in intensive care units. The enzymatic resistance to carbapenems is encoded by different β-lactamases belonging to A, B or D Ambler class. Besides compromising the activity of last-resort antibiotics, CRE have spread from the clinical to the environmental sectors, in all geographic regions. The purpose of this review is to present present and future perspectives on CRE-associated infections treatment.

Keywords: Carbapenem-resistant Enterobacterales (CRE); multi-drug resistance; novel antibiotics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Major resistance mechanisms associated with carbapenem-resistant Enterobacterales (CRE) infections.
See this image and copyright information in PMC

References

    1. Wolrd Health Organization . WHO Priority Pathogens List for R&D of New Antibiotics. WHO; Geneva, Switzerland: 2017.
    1. Lee C.-M., Lai C.-C., Chiang H.-T., Lu M.-C., Wang L.-F., Tsai T.-L., Kang M.-Y., Jan Y.-N., Lo Y.-T., Ko W.-C., et al. Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. J. Microbiol. Immunol. Infect. 2017;50:133–144. doi: 10.1016/j.jmii.2016.12.001. - DOI - PubMed
    1. D’Angelo R.G., Johnson J.K., Bork J.T., Heil E.L. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin. Pharmacother. 2016;17:953–967. doi: 10.1517/14656566.2016.1154538. - DOI - PubMed
    1. Ambler R.P. The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 1980;289:321–331. doi: 10.1098/rstb.1980.0049. - DOI - PubMed
    1. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., Alberti S., Bush K., Tenover F.C. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2001;45:1151–1161. doi: 10.1128/AAC.45.4.1151-1161.2001. - DOI - PMC - PubMed

LinkOut - more resources